← All trials
NCT04564716
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 28, 2020
- Primary completion
- Mar 28, 2021
- Completion date
- Apr 10, 2021
- First posted
- Sep 25, 2020
- Last posted
- Dec 2, 2020
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of RussiaLead sponsor
- Government of RussiaCollaborator
- iPharmaStudy chair
- iPharmaCollaborator
- Government of RussiaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.